Understanding long-term effects of Gram-negative pneumonia
Determinants of long-term outcomes and heterogeneity in Gram-negative community-acquired pneumonia
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF WASHINGTON · NIH-10899457
This study is looking at how people who have survived a serious lung infection called pneumonia, caused by a specific germ, do over time after leaving the hospital, and it aims to find out what factors might lead to health problems later on so that doctors can provide better care for those who need it.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10899457 on ClinicalTrials.gov |
What this research studies
This research investigates the long-term health outcomes of patients who have survived community-acquired pneumonia (CAP) caused by the Gram-negative bacterium Burkholderia pseudomallei. It aims to identify the factors that contribute to adverse outcomes after hospital discharge, focusing on the immune response and the severity of the illness at admission. By analyzing a large group of patients in Northeast Thailand, the study seeks to uncover biological markers and subgroups of patients that may require different treatment approaches. This could lead to better-targeted therapies for those affected by this serious infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been hospitalized with community-acquired pneumonia caused by Burkholderia pseudomallei.
Not a fit: Patients with pneumonia caused by other pathogens or those who have not been hospitalized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better long-term health outcomes for patients recovering from Gram-negative pneumonia.
How similar studies have performed: Previous research has shown that understanding the immune response in pneumonia can lead to better outcomes, suggesting this approach has potential for success.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COSTON, TAYLOR DAVID — UNIVERSITY OF WASHINGTON
- Study coordinator: COSTON, TAYLOR DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Disease